INDV

Peers: JNJ VRTX PFE ABBV BMY GILD LLY BIIB TEVA NBIX

| Held by: IJR IWM VXF SPSM IJT IWO SLYG VTWO SCHA VIOO

Index	RUT	P/E	18.37	EPS (ttm)	1.66	Insider Own	3.29%	Shs Outstand	125.00M	Perf Week	-1.17%
Market Cap	3.81B	Forward P/E	8.86	EPS next Y	3.44	Insider Trans	0.14%	Shs Float	120.67M	Perf Month	-11.23%
Enterprise Value	3.97B	PEG	0.59	EPS next Q	0.65	Inst Own	94.98%	Short Float	8.30%	Perf Quarter	-13.79%
Income	209.00M	P/S	3.08	EPS this Y	24.86%	Inst Trans	1.07%	Short Ratio	4.36	Perf Half Y	32.78%
Sales	1.24B	P/B	-	EPS next Y	10.25%	ROA	16.53%	Short Interest	10.01M	Perf YTD	-14.99%
Book/sh	-0.78	P/C	19.56	EPS next 5Y	15.04%	ROE	-	52W High	38.00 -19.74%	Perf Year	206.53%
Cash/sh	1.56	P/FCF	-	EPS past 3/5Y	- -	ROIC	97.66%	52W Low	8.64 253.01%	Perf 3Y	81.94%
Dividend Est.	-	EV/EBITDA	10.50	Sales past 3/5Y	11.20% 13.88%	Gross Margin	82.10%	Volatility	4.78% 5.09%	Perf 5Y	252.60%
Dividend TTM	-	EV/Sales	3.20	EPS Y/Y TTM	751.75%	Oper. Margin	29.03%	ATR (14)	1.64	Perf 10Y	162.93%
Dividend Ex-Date	-	Quick Ratio	0.55	Sales Y/Y TTM	4.38%	Profit Margin	16.85%	RSI (14)	36.37	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.71	EPS Q/Q	410.00%	SMA20	-5.18%	Beta	1.21	Target Price	46.86
Payout	0.00%	Debt/Eq	-	Sales Q/Q	20.13%	SMA50	-8.71%	Rel Volume	1.57	Prev Close	30.53
Employees	838	LT Debt/Eq	-	Earnings	Feb 26 BMO	SMA200	14.35%	Avg Volume	2.30M	Price	30.50
IPO	Dec 29, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	21.66% 17.14%	Trades		Volume	4,095,410	Change	-0.10%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-06-25	Initiated	H.C. Wainwright	Buy	$27
Jul-22-25	Resumed	Jefferies	Buy	$20
Jan-28-25	Initiated	Rodman & Renshaw	Buy	$16
Jul-23-24	Initiated	Piper Sandler	Overweight	$22
Apr-03-24	Initiated	Craig Hallum	Buy	$37
Jul-13-23	Initiated	Northland Capital	Outperform	$35

Mar-17-26 12:02PM	National Survey Finds Only 58% of U.S. Correctional Facilities Offer Medications for Opioid Use Disorder (GlobeNewswire)
Mar-12-26 08:30PM	Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering (GlobeNewswire) -6.00%
07:00AM	Indivior Announces Proposed Convertible Senior Notes Offering (GlobeNewswire)
Mar-11-26 09:00AM	New Study Shows Adherence to Monthly Injectable Buprenorphine Linked to Lower Healthcare Utilization and Costs in Opioid Use Disorder (GlobeNewswire)
Mar-09-26 12:35PM	Implied Volatility Surging for Indivior Pharmaceuticals Stock Options (Zacks)
08:05PM	Loading…
Feb-26-26 08:05PM	Indivior PLC Q4 2025 Earnings Call Summary (Moby)
09:55AM	Indivior Pharmaceuticals Inc. (INDV) Tops Q4 Earnings and Revenue Estimates (Zacks)
09:16AM	Indivior Q4 Earnings Call Highlights (MarketBeat)
07:00AM	Indivior Reports Fourth Quarter and Full-Year 2025 Financial Results (GlobeNewswire)
Feb-24-26 07:00AM	Indivior to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-19-26 09:45AM	Indivior Pharmaceuticals to Report Q4 Earnings: What's in the Cards? (Zacks)
Jan-28-26 07:00AM	Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on February 26?? (GlobeNewswire)
Jan-26-26 07:00AM	Indivior Announces Completion of Redomiciliation to the United States (GlobeNewswire)
Jan-21-26 07:17AM	Strength Seen in Ardelyx (ARDX): Can Its 15.0% Jump Turn into More Strength? (Zacks)
04:54AM	'Follow The Money,' Not The Tariff Noise, Says Expert, Spotlights This New S&P Data Center Cooling Stock Among Top Picks (Benzinga)
09:19AM	Loading…
Jan-13-26 09:19AM	Sanofi's Teizeild Gets EU Approval for Treating Type 1 Diabetes (Zacks)
Jan-12-26 10:14AM	PCRX Stock Down 10% as Preliminary Q4 Revenues Miss Estimates (Zacks)
10:08AM	TEVA Signs Deal With RPRX to Accelerate Development of Vitiligo Drug (Zacks)
08:43AM	Take the Zacks Approach to Beat the Markets: Indivior, FIGS & Ulta Beauty in Focus (Zacks)
Jan-10-26 02:57PM	Indivior PLC (INDV) Announces Full-Year 2026 Financial Guidance (Insider Monkey)
Jan-09-26 11:46AM	AMRN Stock Up 17% as Preliminary Q4 Sales Beat Expectations (Zacks)
Jan-08-26 11:09AM	GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug (Zacks)
08:57AM	4 Stocks Trading Near 52-Week High With Room to Rise Further (Zacks)
07:00AM	Indivior Provides Full-Year 2026 Financial Guidance and Business Update (GlobeNewswire)
Jan-07-26 11:45AM	FDA Grants Breakthrough Therapy Designation to ALKS' Narcolepsy Drug (Zacks)
09:53AM	OTLK Stock Crashes 67% in a Week: Here's What You Need to Know (Zacks)
Jan-06-26 11:53AM	ALT Stock Up 17% After Pemvidutide Gets FDA Breakthrough Tag for MASH (Zacks)
Dec-30-25 10:32AM	Why This Top 100 Stock to Buy Is Getting Cheaper Even as It Soars Higher (Barchart)
Dec-22-25 07:00AM	Indivior Announces Inclusion in the S&P SmallCap 600 Index (PR Newswire)
06:00AM	2026 outlook: Small-cap biotechs may fill gaps on drug pipelines (Yahoo Finance Video)
11:30AM	Loading…
Dec-17-25 11:30AM	New Study Shows Extended-Release Buprenorphine Safely Delivers Rapid, Clinically Meaningful Reductions in Opioid Use and Supports Abstinence in High-Risk Populations (PR Newswire)
Dec-05-25 05:49PM	CRH, Carvana and Comfort Systems USA Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 (PR Newswire)
Nov-20-25 04:01PM	Indivior Concludes Legacy U.S. Department of Justice Matter (PR Newswire)
Nov-19-25 09:21AM	Indivior to Participate in the Piper Sandler 37th Annual Healthcare Conference (PR Newswire)
Nov-07-25 08:37AM	4 Must-Buy Efficient Stocks to Enrich Your Portfolio in 2025 (Zacks)
Nov-06-25 03:25PM	3 Top Ranked Stocks that are the Best of the Best (Zacks)
Nov-03-25 08:00AM	Indivior Presents New Real-World Evidence at AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine (PR Newswire) +6.23%
Oct-31-25 10:03AM	Indivior (INDV) Jumps to New High on Earnings Blowout, Optimistic Outlook (Insider Monkey)
Oct-30-25 04:22PM	Indivior PLC (INDV) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com) +15.41%
02:18PM	Here's Why Indivior Stock Soared 15% Today (Motley Fool)
08:30AM	Indivior PLC (INDV) Beats Q3 Earnings and Revenue Estimates (Zacks)
07:00AM	Indivior Reports Third Quarter 2025 Financial Results and Raises Full-Year 2025 Financial Guidance (PR Newswire)
Oct-29-25 09:40AM	Indivior PLC (INDV) Q3 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Oct-28-25 10:00AM	Indivior to Participate in the Stifel 2025 Healthcare Conference (PR Newswire)
Oct-23-25 09:21AM	Indivior PLC (INDV) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Oct-16-25 04:04PM	Indivior to Report Third Quarter 2025 Financial Results and Host Webcast on October 30th (PR Newswire)
Oct-15-25 08:00AM	Clinical Evidence Supports Rapid SUBLOCADE Induction as a Strategy to Improve Retention in Opioid Use Disorder Treatment (PR Newswire)
Oct-01-25 08:00AM	Indivior Proposes New Corporate Structure to Achieve U.S. Domiciliation (PR Newswire)
Sep-30-25 12:47PM	Indivior PLC (INDV) Raises 2025 Guidance After Q2 Revenue Hits $302M (Insider Monkey)
Sep-10-25 12:00PM	What Makes Indivior PLC (INDV) a Strong Momentum Stock: Buy Now? (Zacks)
Sep-09-25 11:57AM	Top 100 Stocks to Buy: Indivior Advances Into Top 50 on Momentum (Barchart)
Aug-20-25 12:00PM	Indivior to Participate in Upcoming Investor Events (PR Newswire)
Aug-06-25 09:36AM	Snap downgraded, Leidos upgraded: Wall Street's top analyst calls (The Fly)
Aug-05-25 12:00PM	All You Need to Know About Indivior (INDV) Rating Upgrade to Strong Buy (Zacks)
10:00AM	Best Momentum Stock to Buy for August 5th (Zacks)
06:16AM	New Strong Buy Stocks for August 5th (Zacks)
Aug-03-25 12:32PM	Indivior Plc (INDV) Jumps 22.8% on Impressive Earnings, Outlook (Insider Monkey)
Aug-01-25 01:23PM	Indivior (INDV) Extends Jump on 3rd Day with 16% Gain (Insider Monkey)
Jul-31-25 08:15AM	Indivior PLC (INDV) Tops Q2 Earnings and Revenue Estimates (Zacks) +16.09%
07:00AM	Indivior Reports Second Quarter 2025 Financial Results and Raises FY 2025 Financial Guidance (PR Newswire)
Jul-30-25 09:43AM	Indivior PLC (INDV) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Jul-28-25 10:06AM	Indivior PLC (INDV) Reinvents Leadership, Moves Listing to Nasdaq (Insider Monkey)
10:00AM	BioCryst Pharmaceuticals (BCRX) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Jul-25-25 02:00AM	Indivior Announces Completion of Cancellation of Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained (PR Newswire)
Jul-24-25 10:00AM	Indivior PLC (INDV) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-23-25 08:00AM	Indivior Real World Evidence Study Finds Medications for Opioid Use Disorder, Particularly Extended-Release Buprenorphine, Reduced Odds of Emergency Department Visits for Patients with Opioid Use Disorder (PR Newswire)
Jul-17-25 09:00AM	Indivior to Report Second Quarter 2025 Financial Results and Host Webcast on July 31st (PR Newswire)
Jul-08-25 08:00AM	Indivior Appoints Vanessa Procter as Executive Vice President of Corporate Affairs (PR Newswire)
Jul-01-25 07:05AM	Indivior (INDV) Moves 5.7% Higher: Will This Strength Last? (Zacks)
Jun-30-25 07:00AM	Indivior Announces Inclusion in the U.S. Russell 2000 and 3000 Indexes (PR Newswire) +5.66%
Jun-27-25 05:45PM	IGC Pharma, Inc. (IGC) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
Jun-24-25 04:12PM	Indivior Appoints Tony Kingsley to the Board of Directors (PR Newswire)
02:07PM	Teladoc (TDOC) Moves 14.4% Higher: Will This Strength Last? (Zacks)
10:40AM	Strength Seen in Nektar (NKTR): Can Its 12.1% Jump Turn into More Strength? (Zacks)
07:56AM	RGC Resources (RGCO) Surges 9.1%: Is This an Indication of Further Gains? (Zacks)
Jun-20-25 03:01AM	Addex Therapeutics Ltd (ADXN) Q1 2025 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
Jun-19-25 09:00AM	Indivior Presents New Data at CPDD Demonstrating that High Buprenorphine Exposure May Improve Treatment Outcomes in High Fentanyl Users (PR Newswire)
Jun-05-25 05:08AM	Wise Plans to Shift Main Listing to US in Latest London Loss (Bloomberg)
Jun-02-25 05:24AM	FTSE pharma giant joins London stock market exodus (The Telegraph)
02:00AM	Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained (PR Newswire)
May-27-25 08:30AM	Indivior Announces Patrick Barry as Chief Commercial Officer (PR Newswire) +5.02%
May-13-25 10:00AM	Indivior to Participate in Upcoming Investor Events (PR Newswire)
May-01-25 10:27AM	New Study Highlights Monthly SUBLOCADE as a Potential Treatment Option for Opioid Use Disorder During and After Pregnancy (PR Newswire)
Apr-28-25 12:12PM	Indivior: Trying To Break Addiction (Seeking Alpha)
Apr-24-25 10:45AM	Indivior PLC (INDV) Q1 2025 Earnings Conference Call Transcript (Seeking Alpha) +13.86%
07:05AM	Indivior PLC (INDV) Q1 Earnings and Revenues Beat Estimates (Zacks)
03:58AM	Indivior Q1 Net Income Declines; Net Revenue Down 6% (RTT News)
02:00AM	Indivior Announces Q1 2025 Financial Results (PR Newswire)
Apr-02-25 04:12AM	Indivior: A Complicated Story Of Both Declining Revenue And Strong Financials (Seeking Alpha)
Mar-31-25 07:51PM	Is Indivior PLC (INDV) the Best Stock to Buy According to Howard Marks' Oaktree Capital Management? (Insider Monkey)
Mar-27-25 05:35PM	Plus Therapeutics (PSTV) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
Mar-04-25 08:40AM	Indivior Announces Further Changes to Board of Directors (PR Newswire) +5.76%
Mar-02-25 06:36PM	Is Indivior PLC (INDV) the Best Small Cap Pharma Stock to Buy Now? (Insider Monkey)
Feb-27-25 02:00AM	Indivior Announces Joseph Ciaffoni Appointed Chief Executive Officer (PR Newswire)
Feb-24-25 02:00AM	Indivior Announces FDA Approval of Label Changes for SUBLOCADE (buprenorphine extended-release) Injection (PR Newswire)
Feb-21-25 02:05AM	Indivior PLC (INDV) (Q4 2024) Earnings Call Highlights: Strong SUBLOCADE Growth and Strategic ... (GuruFocus.com) -6.01%
Feb-20-25 02:13PM	European Addiction-Focused Indivior Stock Falls As Drugmaker Warns Lower Revenues In 2025 Despite Q4 Earnings Beat (Benzinga) -17.60%
09:11AM	Earnings To Watch: Indivior PLC (INDV) Reports Q4 2024 Result (GuruFocus.com)
07:05AM	Indivior PLC (INDV) Q4 Earnings Meet Estimates (Zacks)
02:00AM	Indivior Announces FY and Q4 2024 Financial Results (PR Newswire)

Indivior Pharmaceuticals, Inc. is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company was founded on December 23, 2014 and is headquartered in North Chesterfield, VA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ryan Barbara	Director	Mar 13 '26	Buy	31.09	8	249	5,724	Mar 13 04:25 PM
Kingsley Stuart A	Director	Mar 06 '26	Buy	31.86	940	29,953	5,582	Mar 11 09:54 AM
Ryan Barbara	Director	Mar 09 '26	Buy	32.56	31	1,009	5,716	Mar 11 08:12 AM
Ryan Barbara	Director	Jan 05 '26	Buy	35.39	775	27,429	1,963	Jan 07 01:51 PM
Humphreys Keith	Director	Jan 05 '26	Buy	35.39	775	27,429	5,802	Jan 07 01:50 PM
NINIVAGGI DANIEL A	Director	Jan 05 '26	Buy	35.39	775	27,429	16,923	Jan 07 01:49 PM
Stejbach Mark	Director	Jan 05 '26	Buy	35.39	775	27,429	16,847	Jan 07 01:48 PM
Wheadon David E.	Director	Jan 05 '26	Buy	35.39	1,771	62,680	14,395	Jan 07 01:47 PM
Cetani Cynthia C	Officer	Nov 07 '25	Proposed Sale	30.65	121,737	3,731,762		Nov 07 04:05 PM
Crossley Mark	Affiliate	Sep 08 '25	Proposed Sale	24.75	26,463	655,000		Sep 08 04:26 PM
Mark Crossley	affiliate	Sep 08 '25	Proposed Sale	24.97	183,938	4,593,151		Sep 08 02:24 PM
Mark Crossley	affiliate	Sep 04 '25	Proposed Sale	24.80	30,000	744,010		Sep 04 12:59 PM
Mark Crossley	affiliate	Aug 28 '25	Proposed Sale	24.43	52,320	1,278,178		Aug 28 12:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Indivior Pharmaceuticals Inc

Upgrade your FINVIZ experience